Litifilimab Phase 2 Durability Impresses, But Pivotal Phase 3 Gap Remains the Defining Risk

Biogen's Litifilimab Shows Durable Efficacy in 52-Week CLE Data

Biogen Inc. announced positive 52-week results from the Phase 2 part of the ongoing AMETHYST Phase 2/3 study of litifilimab in cutaneous lupus erythematosus (CLE). The data, presented at EADV 2026, showed continued clinical improvements in skin disease activity, with 27.2% of participants achieving clear or almost clear skin (CLA-IGA-R 0-1) and 28.8% achieving a 70% or greater reduction in CLASI A at Week 52. Participants who switched from placebo to litifilimab experienced rapid onset of effect within four weeks. The safety profile remained consistent with previous studies, with no new safety signals identified. Litifilimab previously received Breakthrough Therapy Designation from the FDA in January 2026.

• Litifilimab demonstrated continued improvement in skin disease activity over 52 weeks, with 27.2% of participants achieving clear or almost clear skin (CLA-IGA-R 0-1) and 28.8% showing a 70% or greater reduction in disease activity (CLASI-70) by Week 52, an increase from Week 24 results.
• The study highlighted a rapid onset of treatment effect, as participants who switched from placebo to litifilimab at Week 24 experienced improvements in skin disease activity as early as four weeks, consistent with initial treatment group findings.
• Litifilimab maintained a consistent safety profile throughout the 52-week treatment period, with no new safety signals identified. The majority of adverse events were mild or moderate, and serious adverse events occurred in a small percentage (3.4%) of participants.
• Litifilimab was granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration (FDA) in January 2026 for the treatment of CLE, underscoring its potential as a first-in-class therapy for this condition.

Litifilimab's Durable Efficacy and Safety in CLE: 52-Week AMETHYST Data

Several recent clinical trials have advanced the evidence base for CLE-targeted therapy. The LILAC study, a phase II randomised controlled trial, evaluated litifilimab (BIIB059) — a monoclonal antibody targeting BDCA2, a plasmacytoid dendritic cell-specific antigen — in patients with CLE. The trial demonstrated superiority of litifilimab over placebo using a skin-directed outcome measure, marking it as the first successful clinical trial for a CLE-targeted therapy. No FDA-approved therapies for CLE currently exist, and litifilimab has been highlighted as a candidate to change that landscape, particularly for severe and refractory disease.

The WILLOW trial (Cohort A) investigated enpatoran, an oral small-molecule TLR7/8 inhibitor developed by Merck Healthcare KGaA, in participants with active skin manifestations of CLE or SLE with mild or no extra-mucocutaneous disease activity and a CLASI-A score of 8 or higher. In this phase 2, randomised, double-blind, placebo-controlled, dose-finding study conducted across 132 centres in 22 countries, 100 participants were analysed for efficacy across four arms (placebo, enpatoran 25 mg, 50 mg, or 100 mg twice daily for 24 weeks). At week 16, enpatoran demonstrated a significant, dose-dependent reduction in CLASI-A score: adjusted mean changes from baseline were -64 percentage points (95% CI -70 to -58) for the 25 mg group, -68 percentage points (-75 to -61) for the 50 mg group, and -72 percentage points (-80 to -64) for the 100 mg group, versus -44 percentage points (-55 to -33) for placebo (p=0.0002 for dose-response relationship). From a safety standpoint, the most common treatment-emergent adverse event was upper respiratory tract infection. Serious adverse events occurred in one participant (4%) in the placebo group, two (8%) in the enpatoran 25 mg group, one (4%) in the enpatoran 100 mg group, and none in the enpatoran 50 mg group.

Supporting the broader mechanistic rationale, a phase Ib randomised, double-blind, placebo-controlled study also evaluated enpatoran across multiple ascending doses in patients with active SLE and CLE. The primary endpoint of safety and tolerability was met: by week 12, treatment-emergent adverse events were reported by 42% of enpatoran-treated patients and 33% of placebo-treated patients, with 96% of TEAEs mild or moderate in severity and no serious TEAEs observed. Enpatoran pharmacokinetics were dose proportional, with peak concentration reached 1–2 hours postdose and an apparent half-life of 6–10 hours. Exploratory endpoints showed rapid, dose-dependent, and reversible suppression of interferon gene signature, and greater reductions in SLE Disease Activity Index 2000, Physician's Global Assessment, and 28-joint count were observed at week 24 with enpatoran versus placebo.

AMETHYST Phase 2: Design, Endpoints, and Patient Population

Several phase 2 randomized controlled trials have evaluated investigational agents in CLE, employing the Cutaneous Lupus Erythematosus Disease Area and Severity Index-Activity (CLASI-A) score as the central efficacy measure. The trials below represent the key interventional studies identified in the literature, spanning anti-BDCA2, JAK inhibitor, and SYK inhibitor mechanisms.

Litifilimab's BDCA2 Targeting: A Novel Approach in CLE

Recent research has identified the type I interferon (IFN) pathway as a central therapeutic target in CLE, with particular focus on plasmacytoid dendritic cells (pDCs) as upstream drivers of IFN-mediated skin inflammation. A phase 1b study of BIIB059, a monoclonal antibody targeting the blood DC antigen 2 (BDCA-2) receptor on pDCs, demonstrated decreased IFN expression and improved cutaneous lupus disease activity with a favorable safety profile. These findings suggest that organ-specific targeting of the type I IFN pathway — rather than broad systemic inhibition of IFN-α or the type I IFN receptor — may represent a more tractable strategy for CLE, and that closing the door on this pathway prematurely would be unwarranted.

Spatial and proteomic profiling of CLE lesional skin has further refined the mechanistic map of disease, revealing novel chemokine ligand-receptor axes as candidate targets. Elevated IFN-inducible CXCR3 ligands, along with upregulation of CCL8 and CXCL6 in lesional samples, point to distinct immune cell recruitment pathways: CD14+CD16+ antigen-presenting cell populations show heightened sensitivity to CXCL6 via CXCR1, while CD14+ cells are more sensitive to CCL8 via CCR2. Upstream of these chemokine signals, keratinocyte injury activates the AIM2–Caspase 8–IL-18 axis, with Olink proteomics confirming upregulation of Caspase 8 and IL-18 in CLE lesional samples, mapping a pathway from keratinocyte damage to lymphocyte recruitment via AIM2-Casp8-IL-18-CXCL6/CXCR1 and CCL8/CCR2, and IFNG/IFNL1-CXCL9/CXCL11-CXCR3.

The Th17/regulatory T cell cytokine axis represents an additional emerging therapeutic frontier in CLE. IL-17 levels are significantly elevated in malar rash patients compared to healthy controls, SLE patients, and DLE patients (p=0.023, p=0.008, and p=0.019, respectively), while IL-23 is significantly elevated specifically in DLE patients versus healthy controls (p=0.019), and IL-6 is significantly elevated across SLE, DLE, and malar rash patients compared to healthy controls (p=0.025). These findings suggest that inhibitors of IL-17, IL-23, and IL-6/IL-6 receptor may offer targeted therapeutic benefit in CLE, with the cytokine profile varying by disease subtype and potentially informing subtype-specific treatment strategies.

Litifilimab's Enduring Promise in Cutaneous Lupus

The recent 52-week data for Biogen's litifilimab in cutaneous lupus erythematosus (CLE) marks a significant milestone in a therapeutic area long underserved by targeted treatments. With no FDA-approved therapies specifically for CLE, patients often rely on unspecific immunosuppressants or off-label use of systemic lupus erythematosus (SLE) drugs. Litifilimab, a monoclonal antibody targeting BDCA2 on plasmacytoid dendritic cells (pDCs), directly addresses a pivotal pathway in lupus pathogenesis by modulating the type I interferon (IFN) response. The sustained clinical improvements observed at Week 52, including a notable proportion of patients achieving clear or almost clear skin, underscore its potential for durable efficacy. This, combined with a rapid onset of action and a consistent safety profile, reinforces the drug's promise.

The FDA's prior Breakthrough Therapy Designation for litifilimab further highlights its potential to fill a critical gap. Strategically, this positions Biogen to potentially establish a first-in-class targeted therapy for CLE, reshaping the treatment landscape and offering a new standard of care. The success in CLE could also pave the way for exploring its utility in other type I IFN-driven autoimmune conditions, including SLE.

However, the path forward is not without considerations. The competitive landscape is evolving rapidly, with other agents like deucravacitinib and anifrolumab demonstrating strong efficacy in CLE, and in some analyses, even superior profiles. Additionally, the observed association with herpes infections, including herpes zoster, warrants ongoing safety monitoring and patient education. Given the inherent heterogeneity of CLE and the diverse inflammatory signatures that can drive the disease, identifying patient subgroups most likely to benefit from pDC-directed therapy will be crucial. Future efforts may focus on refining patient stratification strategies to optimize therapeutic outcomes and ensure litifilimab reaches those who stand to gain the most. This development underscores the growing shift towards precision medicine in autoimmune diseases, demanding a nuanced understanding of disease biology and treatment response.